Welcome to our dedicated page for Can-Fite BioPharma Ltd. news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. stock.
Can-Fite BioPharma Ltd. (CANF) is a clinical-stage biotechnology company whose news flow centers on the development of orally administered small-molecule drugs targeting the A3 adenosine receptor. On this page, readers can follow company announcements on clinical trial progress, regulatory designations, patent developments, financing events, and corporate actions related to its oncology, liver disease, inflammatory, and sexual dysfunction programs.
Recent news has highlighted pivotal and mid-stage clinical studies, including a Phase III trial of Namodenoson in advanced hepatocellular carcinoma, a Phase IIb trial in MASH, and a Phase IIa study in pancreatic cancer. The company has also reported compassionate use cases in advanced liver disease and cirrhosis, as well as long-term survival outcomes in liver cancer patients treated with Namodenoson. For Piclidenoson, updates include Phase III psoriasis development and protocol preparation for rare diseases such as Lowe Syndrome, along with preclinical findings in vascular dementia models.
News items also cover CF602, an A3AR allosteric modulator in development for erectile dysfunction, including patent allowances and grants in markets such as Brazil, the United States, and Europe. Can-Fite regularly reports on its intellectual property strategy, out-licensing and distribution agreements for human and veterinary indications, participation in industry conferences, and capital markets activities such as public offerings, warrant amendments, and share structure changes like reverse splits and ADS ratio adjustments.
Investors and observers can use this CANF news feed to monitor key milestones that may affect the company’s clinical pipeline, regulatory interactions, partnering discussions, and financial position over time.
Can-Fite (NYSE:CANF) announced that the Israeli Patent Office allowed patent No. 284463 for the use of A3 adenosine receptor agonists, including Namodenoson, to induce fat loss and treat obesity. The allowance expands global IP after prior grants in the US, Canada and Australia.
The company cited a peer-reviewed International Journal of Obesity study supporting Namodenoson’s anti-obesity effect and noted the global obesity therapeutics market is projected at $60.5 billion by 2030 (CAGR ~22%).
Can-Fite (NYSE American: CANF) entered a definitive agreement for immediate exercise of warrants to buy up to 795,869 ADSs at a reduced price of $5.00 per ADS (originally $9.34). Closing is expected on or about March 5, 2026, subject to customary conditions.
The company will issue new unregistered warrants to purchase up to 1,591,738 ADSs, exercisable at $5.00 until the 24-month anniversary of the Resale Registration Statement. Gross proceeds are expected to be approximately $4.0 million before placement agent fees and expenses. Net proceeds will fund R&D, clinical trials, working capital and general corporate purposes.
Can-Fite (NYSE American: CANF) reported that its Phase 2a open-label study of namodenoson in advanced pancreatic ductal adenocarcinoma met its primary endpoint of safety. The trial enrolled 20 heavily pretreated patients; namodenoson was very well tolerated with no new safety signals identified.
Survival follow-up is ongoing; one-third of patients were alive at data cut-off. Namodenoson holds FDA Orphan Drug Designation for pancreatic cancer and remains under further clinical evaluation.
Can-Fite (NYSE American: CANF) announced a peer-reviewed International Journal of Obesity publication (Feb 17, 2026) showing namodenoson reduced adipocyte proliferation and lipid accumulation in vitro and produced a statistically significant reduction in weight gain in a murine high-fat diet model after four weeks.
According to the company, findings align with prior Phase IIa MASH data showing reduced liver fat and body weight, highlight modulation of adiponectin and multiple metabolic pathways, note a favorable safety profile, and point to potential expansion into the growing obesity treatment market.
Can-Fite (NYSE American: CANF) announced the Canadian Patent Office issued a notice of allowance for Canadian Patent Application No. 3,126,002, covering Namodenoson for use as an anti-obesity therapy.
The allowance adds Canadian IP to existing U.S. and Australian obesity/metabolic patents, cites preclinical fat reduction and a MASH Phase IIa observation of 2.3% weight loss after 3 months with increased adiponectin, and highlights an excellent oral safety profile.
Can-Fite (NYSE American: CANF) reported that a patient with advanced decompensated liver cirrhosis treated with Namodenoson under compassionate use achieved clinical stabilization and subsequently underwent a successful liver transplantation on Feb 5, 2026. The single-case outcome suggests Namodenoson may serve as a supportive bridge to transplant.
The drug is an oral A3 adenosine receptor agonist being evaluated in advanced liver diseases, with prior studies showing a favorable safety profile.
Can-Fite (NYSE American: CANF) completed patient enrollment in its multicenter, open-label Phase 2a study of Namodenoson in advanced pancreatic adenocarcinoma on Jan 20, 2026. The trial evaluates safety (primary endpoint), clinical activity, and pharmacokinetics with oral Namodenoson 25 mg twice daily in continuous 28-day cycles. To date the drug has demonstrated a favorable safety profile. The study is led by Prof. Salomon Stemmer at Davidoff Center, Rabin Medical Center. Can-Fite expects top-line efficacy data in Q3 2026. Namodenoson is a selective A3 adenosine receptor agonist with preclinical anti-tumor activity and has received FDA Orphan Drug Designation for pancreatic cancer.
Can-Fite (NYSE American: CANF) announced that the Brazilian Patent Office granted Patent No. BR112015002697-4 for “Use of an A3 Adenosine Receptor Agonist for the Treatment of Sexual Dysfunction” on Dec. 26, 2025.
The patent provides intellectual‑property protection in Brazil for Can‑Fite’s A3AR agonists for sexual dysfunction, complements the company’s global patent portfolio, and may support future partnering or commercialization opportunities in Latin America. Can‑Fite cites preclinical and clinical data suggesting A3AR activation may modulate signaling related to erectile and sexual function.
Can-Fite (NYSE American: CANF) announced a 1-for-3,000 reverse split of ordinary shares following shareholder approval on November 10, 2025.
The split will be recorded on the Tel-Aviv Stock Exchange on January 2, 2026, with first TASE trading of consolidated shares on January 5, 2026. Concurrently the ADS ratio will change from 1 ADS = 300 ordinary shares to 1 ADS = 2 ordinary shares, effective on the NYSE American on January 5, 2026, requiring an exchange of every 20 ADS for 1 new ADS.
The company will reduce authorized ordinary shares from 42,000,000,000 to 14,000,000 and issue no fractional ordinary shares (rounded up); ADS fractional entitlements will be aggregated and sold by the depositary bank. New CUSIP: 13471N409.
Can-Fite BioPharma (NYSE American: CANF) provided a clinical and financial update on Dec 16, 2025. Key clinical programs: Namodenoson is enrolling a pivotal Phase III in advanced hepatocellular carcinoma (Child-Pugh B7) with an interim analysis ~Q4 2026, a Phase IIb in MASH (following positive Phase IIa published data), and a Phase IIa in pancreatic cancer with data expected Q2 2026. Piclidenoson is enrolling a pivotal Phase III in psoriasis with an interim readout ~Q2 2026. Financials: cash and short-term deposits were $6.45M as of June 30, 2025; the company raised $5M in a July 28, 2025 public offering and $2.2M via ATM in Nov 2025.